Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. by Mansoor, Leila Essop. et al.
TRIALS
Mansoor et al. Trials 2014, 15:496
http://www.trialsjournal.com/content/15/1/496STUDY PROTOCOL Open AccessAssessing the implementation effectiveness and
safety of 1% tenofovir gel provision through
family planning services in KwaZulu-Natal,
South Africa: study protocol for an open-label
randomized controlled trial
Leila E Mansoor1*, Quarraisha Abdool Karim1,2, Kathryn T Mngadi1, Sarah Dlamini1, Carl Montague1,
Nelisiwe Nkomonde1, Nomzamo Mvandaba1, Cheryl Baxter1, Tanuja N Gengiah1, Natasha Samsunder1,
Halima Dawood1, Anneke Grobler1, Janet A Frohlich1 and Salim S Abdool Karim1,2,3Abstract
Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a
39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A
confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of
opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of
tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services.
The CAPRISA 008 implementation trial provides an opportunity to provide post-trial access to tenofovir gel while
generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can
achieve similar levels of adherence as the CAPRISA 004 trial.
Methods/design: This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700
sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral
prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study
duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort
will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible
participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or
through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement
approach will be used to assist the FP services to expand their current services to include tenofovir gel provision.
Discussion: This protocol aims to address an important implementation question on whether FP services are able
to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of
tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps
identify a potential avenue for future scale-up of microbicides within the public health system of South Africa.
Trial registration: This trial was registered with the South Africa Department of Health (reference: DOH-27-0812-4129)
and ClinicalTrials.gov (reference: NCT01691768) on 05 July 2012.
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The Joint United Nations Program on HIV/AIDS and
the World Health Organization estimate that nearly half
of the 33.4 million people living with HIV/AIDS in the
world are women [1]. In sub-Saharan Africa, women ac-
count for 59% of all infected adults, and HIV-positive
women aged 15 to 24 years outnumber their male peers
by three to one, representing 76% of the total cases in
that age group [2,3]. These figures highlight the vulner-
ability of women, particularly young women, to becom-
ing infected with HIV in sub-Saharan Africa.
In addition to biological factors [4-6] that make wo-
men more vulnerable than men to acquiring HIV during
sex, certain sexual behavior patterns place young women
at high risk, including partnering with older men who
are more likely to be infected [7], multiple concurrent
relationships [8], low marriage rates [9], low consistent
condom use rates [10,11], and limited skills in nego-
tiating safer sex practices. Gender-based violence increa-
ses vulnerability [12], and poverty increases reliance on
transactional sex for survival [13]. Women are often un-
able to convince their male partners, especially husbands
and regular partners, to use condoms or to practice mo-
nogamy. Despite the greater vulnerability of women, they
have few options to reduce the transmission and acquisi-
tion of HIV. New technologies to prevent the sexual trans-
mission of HIV in women, such as topical microbicides,
are urgently needed.
Topical microbicides, an HIV prevention strategy that
women can initiate or control, were first proposed more
than two decades ago [14]. Since then several candidate
microbicides have entered effectiveness trials to assess
their impact on the prevention of HIV infection, in-
cluding surfactants that disrupt cell membranes [15-18],
polyanions that prevent attachment to target cells in the
vagina [19-21], and products that maintain low vaginal
pH in the presence of ejaculate [22]. Most of the candi-
date microbicides that have been tested in late stage pre-
vention trials have not shown protection against HIV
infection [15-17,20,23,24], and some products were even
potentially harmful [18,19,23].
Currently, research on microbicides is focused on as-
sessing potential antiretroviral agents in various formula-
tions and dosing strategies for their ability to prevent
HIV infection. Tenofovir, a nucleotide analog with po-
tent activity against retroviruses, is the candidate in the
most advanced stage of testing. It was originally formu-
lated for oral use as tenofovir disoproxil fumarate (TDF)
[25] and its efficacy in suppressing viral replication, fa-
vorable safety profile, long half-life [26] and accessibility
made it an ideal choice to be formulated into a microbi-
cide gel.
In the Centre for the AIDS Programme of Research
in South Africa (CAPRISA) 004 trial, tenofovir gel wasshown to be safe [27] and provided an overall protect-
ive effect of 39% against HIV infection and 51% against
herpes simplex virus type 2 (HSV-2) infection among
women in KwaZulu-Natal, South Africa [28,29].
Although the results of the CAPRISA 004 trial still
need to be confirmed, tenofovir gel could potentially fill
an important HIV prevention gap, especially for women
unable to successfully negotiate mutual monogamy or con-
dom use [28]. Mathematical modeling of the CAPRISA
004 results showed that over the next two decades, tenofo-
vir gel could prevent an estimated 1.3 million new HIV in-
fections and over 800,000 deaths in South Africa alone
[30]. These estimates do not take into account the added
benefit of preventing HSV-2 infection that doubles the risk
of acquiring HIV [31]. Thus, implemented on a broader
scale, tenofovir gel could save millions of lives over time,
thereby helping to ease the global burden of providing HIV
treatment and care.
A few other recent studies have evaluated prophy-
lactic use of antiretrovirals (ARVs) in women living in
sub-Saharan Africa with disappointing results. The FEM-
PrEP trial of daily oral Truvada (a combination of TDF
and emtricitabine (FTC)) among women living in Uganda,
South Africa, and Tanzania did not find a significant re-
duction in HIV incidence in the treatment arm compared
to the placebo arm [32]. The Microbicide Trials Network
VOICE trial, which tested daily dosing of tenofovir gel,
oral TDF and oral TDF-FTC in women living in Uganda,
South Africa, and Tanzania, also found no significant pro-
tective effect against HIV infection in any of the inter-
vention groups [33]. Drug-level testing in FEM-PrEP and
VOICE revealed very low adherence rates, which may
have contributed to the lack of efficacy found in these
trials [32,33].
The difficulty in achieving high adherence to tenofovir
gel or oral pre-exposure prophylaxis in trials of women
in sub-Saharan Africa underscores the need for research
into the implementation of pre-exposure prophylaxis in
the region. The potential impact of a prophylactic inter-
vention such as tenofovir gel could be severely hindered
if it is not effectively implemented through the health
system and made accessible to its target population. Thus,
a good understanding of the strengths and challenges of
local health services delivery systems prior to roll-out is
imperative to the success of a new intervention.
One approach to programmatic scale-up of tenofovir
gel within the public health system in South Africa is to
integrate its provision into family planning services. Large
numbers of sexually active women already utilize family
planning services on a regular basis, and family planning
staff are knowledgeable about sexual reproductive health
and have experience providing counseling and adherence
support. Additionally, family planning services are inte-
grated into primary health care (PHC) services and are
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delivery system, making these services widely available
throughout South Africa. For these reasons, integrating
HIV prevention and family planning services could be
achieved with little additional burden to family planning
providers and to the great benefit of their clientele.
Empiric evidence is needed to assess whether inte-
grating tenofovir gel provision into family planning ser-
vices can achieve similar, if not better, levels of safety
and gel use than that observed in the CAPRISA 004 trial.
CAPRISA 008 (protocol version 2.0, dated 23 November
2011) will rigorously test whether the quality improve-
ment (QI) approach can be utilized in strengthening exist-
ing family planning services to the extent that they can
incorporate tenofovir gel provision in their services and
provide rapid, efficient, safe and effective access to a much
needed product. Additionally, by including participants
from CAPRISA 004 as participants in this study, a priority
population will gain access to tenofovir gel and generate




This is a two-arm, open-label, randomized controlled
non-inferiority trial.
Study setting
This study will be conducted at the urban and rural
CAPRISA Clinics that participated in the CAPRISA 004
study and their neighboring public sector PHC clinics
where family planning services are provided in KwaZulu-
Natal, South Africa. The CAPRISA Vulindlela Clinic, the
rural control site for this study, is situated in Vulindlela, a
rural sub-district with approximately 90,000 residents
located in the KwaZulu-Natal midlands. The Vulindlela
clinic adjoins the Mafakathini PHC clinic, which ser-
vices an average of 500 clients per month seeking family
planning services and will serve as the rural intervention
site for CAPRISA 008.
The CAPRISA eThekwini Clinic, the urban control site
for CAPRISA 008, and the Prince Cyril Zulu Communic-
able Disease Centre (PCZCDC) are situated in Warwick
triangle, which is a public transportation hub for buses,
“minibus” taxis and the commuter rail in Durban’s Central
Business District. The PCZCDC, a PHC clinic of the
Durban City Health Department, is primarily desig-
nated for the diagnosis and treatment of sexually trans-
mitted infections (STIs) and tuberculosis but also offers
family planning services to an average of 100 clients
per month. It was planned that PCZCDC would serve
as the urban intervention site for CAPRISA 008, but
municipal approval to use the clinic for this purpose is
still pending. In order to meet ethical obligations forpost-trial gel access for CAPRISA 004 participants while
awaiting municipal approval, a family planning clinic was
created within the eThekwini clinic and will be utilized as
the urban intervention site.
In order to facilitate the process of integrating tenofo-
vir gel into existing family planning services during this
study, a QI approach will be utilized to assist public sec-
tor family planning services with expanding their current
service delivery to include tenofovir gel provision. The
QI approach seeks to design systems for maximum ef-
fectiveness, efficiency, and adaptability and to dissemi-
nate the best models for health service delivery at the
most rapid rate possible [34,35]. Health care QI princi-
ples and the Model for Improvement provide an effective
approach to help close the gap between evidence-based
knowledge and the ability of health systems to implement
large-scale programs [35,36]. Health systems are strength-
ened using small scale, rapid cycles of improvement that
are designed and implemented by local providers to de-
velop reliable processes for service delivery through men-
tored coaching and support.
Study population
The study will include a maximum of 700 women who
previously participated in an ARV prevention study and
are willing to use tenofovir gel through this open-label
study at the CAPRISA Vulindlela and eThekwini Clinics
and their neighboring primary care clinics.
HIV prevalence and incidence rates among source
populations
Annual antenatal surveys conducted by CAPRISA have
shown that the prevalence of HIV infection in pregnant
women in Vulindlela has increased from 32.4% (95% CI,
27.5 to 37.3) in 2001 to 44.2% (95% CI, 39.4 to 49.0) in
2004. A pre-CAPRISA 004, prospective cohort study con-
ducted from 2004 to 2005 that recruited women from the
Mafakathini PHC clinic and the PCZCDC found a base-
line HIV prevalence of 35.7% and 59.3%, respectively [37].
More recently, the CAPRISA 004 trial found an overall
HIV incidence rate of 9.1 per 100 women years (95% CI,
6.9 to 11.7) at the urban and rural sites [28].
Eligibility criteria
Women aged 18 years and older who previously partici-
pated in an ARV prevention study are considered eligible
if they are sexually active, HIV-negative, not pregnant,
agree to use a non-barrier form of contraceptive for the
duration of the trial, and are currently utilizing or agree to
attend designated public sector family planning services.
Volunteers who have a creatinine clearance <50 ml/min,
as estimated using the method of Cockcroft and Gault
[38] or have any other condition that, based on the
opinion of the Investigator or designee, would preclude
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study unsafe, complicate interpretation of study outcome
data, or otherwise interfere with achieving the study ob-
jectives will be excluded from the study.Participant retention
The target retention rate is 90% per annum and partici-
pants will be tracked by the Protocol Team. Once a par-
ticipant is enrolled in the study, study staff will make
every reasonable effort to ensure adequate locator infor-
mation is available for follow-up tracking. Participants
will be tracked telephonically and/or by home visit, if ne-
cessary. Retention efforts will be conducted by the same
team for both arms and have been standardized across
study arms.Participant withdrawal
Participants may voluntarily withdraw from the study
for any reason at any time. Designated study staff may
also withdraw participants from the study in order to
protect their safety. Participants may also be withdrawn
if the South African Medicines Control Council (MCC)
or the University of KwaZulu-Natal’s (UKZN) Biomedical
Research Ethics Committee (BREC) terminates the study
prior to its planned end date.Co-enrollment guidelines
Participants in this study may not take part in any other
concurrent research studies that would interfere with
the objectives of this study. The determination of whe-
ther participation in another study would be exclusion-
ary for a given participant will be made by the Principal
Investigators. Approved co-enrollment in other concur-
rent protocols will be documented.Study procedures
Informed consent
Informed consent is obtained from each study partici-
pant in English or isiZulu (the local African language)
prior to screening and enrollment, in accordance with
Good Clinical Practice guidelines. Consent for specimen
storage is also sought. Participants are provided with
copies of their informed consent forms if they are willing
to receive them. An impartial witness is required for the
entire informed consent process with any participant
who is illiterate or whose literacy is limited. Documenta-
tion of the presence of a witness will be achieved through
their signature on the informed consent document. Il-
literate participants will indicate their consent via use of
their mark (finger/thumb print) on the informed consent
documents.Recruitment, screening, and enrollment
Eligibility for the study is assessed in a step-wise manner
at screening and enrollment. Potential participants are
invited to screen for the study and asked to provide in-
formed consent for screening. They receive pre-test coun-
seling and two rapid HIV tests are performed. Post-test
counseling is provided and those testing positive or inde-
terminate on at least one rapid test are referred to one of
several HIV/AIDS treatment programs. If both HIV test
results are negative, the potential participant is asked to
provide demographic information, behavioral eligibility in-
formation and locator information and undergoes a blood
draw for creatinine levels and urine pregnancy testing.
If potential participants remain eligible based on their
creatinine clearance test results, they will undergo a phy-
sical and pelvic examination with genital specimen collec-
tion for storage. Women who meet all the study eligibility
criteria will be asked to provide informed consent and are
thereafter enrolled in the study. Blood will be drawn for
hematology, liver function tests, blood chemistry tests,
serology, hepatitis B virus assays and serum and plasma
archive.
CAPRISA 008 is a post-trial access study and will main-
tain an open cohort for the duration of the study.
Randomization
Enrolled participants will be assigned at random to one
of the two study arms in a 1:1 ratio. The randomization
list used to assign individual study participants to one of
the two arms will be generated by a randomization stat-
istician who is not otherwise involved in the study. This
statistician will use a randomly permuted block design,
stratified by site. The randomization statistician will pro-
vide the site with sealed, opaque randomization envelopes,
sequentially labeled by a unique participant identifier.
These envelopes will be assigned in sequential order to
eligible study participants. Study arm allocation will be
concealed until after a participant is deemed eligible to
participate in the study. This is an open label trial, and
there will be no blinding after the envelope is opened.
After completion of randomization procedures, partici-
pants who are randomized to the intervention arm will
be escorted to the family planning clinic for adherence
counseling and gel dispensation.
Study intervention
Participants randomized to the intervention arm will re-
ceive tenofovir gel through the Mafakathini PHC clinic
in Vulindlela and the CAPRISA family planning clinic or
PCZCDC in eThekwini. A QI approach will be used at
the intervention sites to assist in the expansion of family
planning services to include tenofovir gel provision. A
QI advisor will work with the staff to conduct a gap ana-
lysis of existing family planning service provision prior
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ternal and internal ideas will be carefully vetted to im-
prove the quality of family planning service delivery.
Once the initial QI process has been completed, a site
initiation assessment will be undertaken to ensure pro-
cedures are in place for the study including procedures
for dispensing tenofovir gel. This two-step approach of
initially strengthening the family planning services and
introducing the tenofovir gel using a QI framework will
create a cadre of service providers who can remain vigi-
lant about the quality of services provided and cope with
unexpected or unanticipated situations. There will not
be any additional QI effort in the control clinics beyond
what is routinely done by the research clinics.
Follow-up visit procedures
Women randomized to the intervention arm will attend
monthly visits at the family planning clinics for the first
3 months of study participation. Thereafter, gel provision
and monitoring will be scheduled to coincide with each
participant’s routinely scheduled family planning visits
(typically every 2 to 3 months). Follow-up visits for wo-
men enrolled into the control arm are scheduled through-
out the study follow-up period on a 28-day schedule. The
visit window around a study visit is 14 days on either side.
Upon enrollment and at each study visit, adherence
counseling will be provided to study participants when
they receive gel supplies. The CAPRISA 004 before and
after dosing strategy will be utilized in the intervention
and control arms of this study. Participants will be ad-
vised to insert the first gel dose up to 12 hours before
sex, insert the second gel dose as soon as possible within
12 hours after sex, and not to insert more than two gel
doses in a 24 hour period (referred to as BAT 24). Ad-
herence counselors will utilize techniques based on mo-
tivational interviewing to address participant-centered
strategies to remember proper dosing, to ensure avail-
ability of gel when away from home and to identify and
discuss various challenges and situations that may im-
pede product use. Counseling will include reminders to
contact study staff with questions about gel use and re-
quests for additional gel supplies.
At each scheduled study visit, enrolled participants in
the intervention and control arm will also be provided
with the following: HIV risk reduction counseling and
male and female condoms; contraception counseling
and provision of contraceptive method of choice; advice
to contact study staff with questions about the study,
with requests for additional counseling, additional con-
doms and gel or contraception, and/or to report adverse
events (AEs).
In addition to the regular follow-up requirements, ad-
ditional procedures, including a pelvic examination, ge-
nital specimen collection, and scheduled blood draws forSTI testing and plasma and serum archive, will be com-
pleted at study months 6, 12, 18, 24, study exit and when
clinically indicated.Laboratory procedures
Serum, plasma, and genital specimens taken at enroll-
ment and designated follow-up visits will be stored for
assessments of markers of safety, risk exposure, product
adherence, activity against STIs, and tenofovir resist-
ance. In addition, stored plasma will be used for retro-
spective ribonucleic acid polymerase chain reaction or
Western blot testing to confirm whether early incident
cases of HIV infection during the trial occurred post-
randomization.Study product considerations
1% Tenofovir gel
Tenofovir gel is a clear, transparent, viscous gel at a con-
centration of 1% (weight per weight). For the purposes
of this study, the gel will be packaged in single-use, indi-
vidually wrapped and labeled pre-filled opaque applica-
tors containing approximately 4 ml of gel.Adherence assessment
Data on adherence to the gel use regimen will be collec-
ted at each study visit via brief interviewer-administered
instruments. Study participants will also be asked to re-
turn all previously dispensed applicators at each visit.
Additionally, genital specimens collected during the trial
at study months 6, 12, 18, 24, study exit and from sus-
pected HIV seroconverters will be archived for analysis
of markers of product adherence to enhance interpret-
ation of the results of the trial.Discontinuation of product
Study participants will be discontinued from using teno-
fovir gel by the Principal Investigators and their desig-
nees in the event that they experience a serious adverse
event (SAE) that is judged by the study clinician or des-
ignee to be related to gel use. Participants who become
pregnant will temporarily discontinue gel use and will
only resume gel use when their pregnancy test reverts to
negative. The Principal Investigators and designees also
may at their discretion discontinue gel use - temporarily
or permanently - among participants who experience an
AE judged to be related to gel use, have a pelvic examin-
ation finding involving deep epithelial disruption that is
not resolving, are unable or unwilling to comply with
study procedures, or otherwise might be put at undue
risk to their safety and well-being by continuing gel use.
Gel use will be permanently discontinued when HIV in-
fection has been confirmed.
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Enrolled study participants may continue use of all
concomitant medications, including prescription, non-
prescription, traditional, and other preparations during
this study. Participants will be encouraged to avoid douch-
ing and the use of vaginally-applied medications/prepara-
tions. All concomitant medications used by participants
throughout the course of the study will be reported on ap-
plicable case report forms (CRFs).Safety monitoring and adverse event reporting
Adverse events and reporting requirements
An AE is defined as any untoward medical or social oc-
currence in a clinical research participant which may or
may not have a causal relationship with tenofovir gel.
Study participants will be provided with contact telephone
numbers and instructed to contact study staff to report
any AEs they may experience, except for life-threatening
events for which they will be instructed to seek immediate
emergency care. All participants reporting an AE will be
followed clinically until the AE resolves or stabilizes. AEs
that are ongoing at the time of study exit will be followed
up for up to 30 days after study exit and then, if not re-
solved, will be referred to a health care provider for fur-
ther follow-up.
For each AE, an assessment of the relatedness to the
study product will be made using the criteria and scale
as outlined in the study specific procedures manual and
graded for severity using the most current National
Institutes for Health Division of AIDS severity grading
system. All AEs will be reported on the appropriate
CRF and will contain at least the date the AE occurred,
a brief description of the event, the relationship to study
product, the action taken, the outcome, date resolved, and
the seriousness of the event.Serious adverse event reporting
A SAE includes any experience that is fatal or life-
threatening, results in persistent or significant disability/
incapacity, requires or prolongs hospitalization, or is a
congenital anomaly. A life-threatening AE means that
the participant was, in the view of the designated study
staff, at immediate risk of death from the condition as
it occurred. All SAEs will be reported on the appro-
priate CRF and, with permission of the participant, re-
cords from all non-study medical providers related to
SAEs will be obtained and required data elements will
be recorded on study CRFs. Notification of deaths will
be recorded by reflecting the medical condition that led
to the death on the appropriate CRF. Reporting SAEs
may require additional detailed reports and follow-up.
All SAEs will be reported to CONRAD, the South African
MCC and the UKZN BREC.Data and safety monitoring
The study statisticians will prepare routine study progress
reports which include reports of AEs experienced by study
participants for review by the Data and Safety Monitoring
Board (DSMB). DSMB members will meet in person and/
or via teleconference throughout the period of study im-
plementation to conduct interim reviews of study progress
across both arms, including rates of participant accrual,
retention, completion of primary and relevant secondary
endpoint assessments, and clinical and laboratory adverse
events including the SAE rate. Any deaths of study partici-
pants or other SAEs will be reviewed and the final deci-
sion taken by the DSMB documented. Following review of
the data during the trial, the DSMB may recommend that
the study proceed as designed, proceed with design modi-
fications, or be discontinued.
Statistical considerations
Primary and secondary endpoints
The primary endpoint for this study is mean gel use, as-
sessed by the number of returned used applicators per
participant per month. This endpoint was chosen be-
cause the CAPRISA 004 trial demonstrated a correlation
between the number of returned used applicators and
the level of effectiveness against HIV infection. The fol-
lowing secondary endpoints will be assessed: clinical and
laboratory adverse event and pregnancy rates; HIV inci-
dence rates; self-reported adherence to the tenofovir gel
dosing strategy; self-reported service acceptability and
completion rates of quarterly HIV and pregnancy testing;
HIV viral load among HIV seroconverters; tenofovir re-
sistance among HIV seroconverters; vaginal cytokines;
HSV-2 and human papilloma virus incidence rates; teno-
fovir levels (and their correlation with HIV and HSV-2
infection rates); self-reported product acceptability.
Power and sample size
A maximum of 700 women, randomized in a 1:1 ratio,
will be enrolled over approximately 12 months. We would
like to demonstrate that the difference in gel use is no
greater than 20% between the two study arms. Since the
mean number of returned used applicators in CAPRISA
004 was five per participant per month, a 20% diffe-
rence in gel use equates to one used applicator per par-
ticipant per month. A maximum sample size of 700
provides >90% power to demonstrate whether gel use
in women attending family planning services is similar
to, but no more than 20% lower, than gel use by women
attending the CAPRISA research clinics, adjusted for
10% loss to follow-up.
Data analysis
The primary objective of this non-inferiority study is to
demonstrate that gel use, as measured by the mean
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per month, in the family planning arm is not more than
20% lower than the CAPRISA clinic arm. The number
of used applicators returned will be compared between
the two treatment arms using an appropriate longitu-
dinal method, such as generalized estimating equations
or linear mixed models, adjusted for site. A one-sided
test will be used to determine whether the difference in
mean gel use between the intervention arm and the
control arm is less than 20%.
Analyses will be performed on an intention-to-treat
(ITT) basis and on the per-protocol and as-treated pop-
ulations. For the ITT analysis, participants will be ana-
lyzed according to the study arm, even if the participant
did not follow the assigned procedures. Because the ITT
analysis could increase the chances of declaring equiva-
lence in a non-inferiority study, per-protocol analyses
will also be conducted and compared to the ITT analyses
before the decision is made to regard the ITT popula-
tion as the primary population.
Data management
Data will be collected on standardized CRFs, which will be
developed by the study team. Source documents will be
maintained in the participant’s medical chart or study file
at the site. CRFs will be faxed to the central CAPRISA Data
Management Server using the DataFax system (Clinical
DataFax Systems Inc., Ontario, Canada). Queries arising
during validation of the data will be recorded in quality
control reports sent to the sites on a regular basis. The ori-
ginal CRFs and related documents will be stored securely
at the sites, both during and after the completion of the
study.
Ethical considerations
Regulatory and ethical review
This study is being conducted under the regulatory
oversight of the South African MCC (reference number:
20110145) and the ethical oversight of UKZN’s BREC
(reference number: BFC 237/010) and in accordance
with International Conference on Harmonization guid-
ance and Good Clinical Practice standards. The study
was initiated after receipt of approval by the MCC (ap-
proval date: 21 May 2012) and UKZN’s BREC (approval
date: 13 September 2012). The study is being conducted
in accordance with all conditions of approval by the
ethics and regulatory committees.
Community involvement and consultation
The CAPRISA Community Program has, through a
consultative process, established CAPRISA Community
Research Support Groups at both the CAPRISA sites
where this study will be conducted. The membership of
these Community Research Support Groups includeslocal community leaders, traditional leaders, leadership
of local HIV/AIDS organizations, previous study partic-
ipants, local health service provider representatives and
HIV-positive local community members. In preparation
for this trial, the CAPRISA Community Program will in-
form, educate and mobilize the community to enhance
community input into the research process.
Confidentiality
Every effort will be made to protect participant privacy
and confidentiality to the extent permitted by law.
Discussion
CAPRISA 004 established proof-of-concept that teno-
fovir gel is safe and effective in preventing HIV infec-
tion in a rigorous clinical trial. Translating these findings
into health service programs poses many challenges that
can be exacerbated in the context of weak health care
delivery systems. The post-trial, pre-licensure window
is a critical period to prepare and devise effective strat-
egies for informing future policy and programmatic
scale-up of new interventions. CAPRISA 008 will an-
swer important implementation questions about how
best to incorporate tenofovir gel into routine family
planning health services in South Africa and how to
make it accessible to women who would benefit most
from this product. By undertaking this study now, prior
to licensure, stakeholders will be better prepared for
widespread roll-out and scaling up of provision of te-
nofovir gel within the public health system of South
Africa.
This study will also add to the growing body of im-
plementation research for HIV prevention. Implemen-
tation science uses the scientific method to investigate
how to integrate research findings and evidence-based
interventions into health care policy and practice [39].
Several recent studies have generated useful data for guid-
ing the implementation of programs to reduce mother-to-
child transmission of HIV and increase uptake of medical
male circumcision for HIV prevention [40-43]. However,
CAPRISA 008 is the first study to evaluate implemen-
tation strategies for an HIV prevention tool that can be
used by women to protect themselves from infection over
a long period of time.
There is increasing consensus that research partici-
pants in developing countries should have post-trial ac-
cess to beneficial interventions based on the ethical
principles of beneficence and justice [44]. During the
waiting period for confirmatory studies and the licen-
sure of tenofovir gel, CAPRISA has a responsibility to
make the gel available to CAPRISA 004 participants
since it is unavailable to them through any other chan-
nel. By inviting CAPRISA 004 participants to take part
in the CAPRISA 008 study, we are able to meet this
Mansoor et al. Trials 2014, 15:496 Page 8 of 9
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data for the future implementation of tenofovir gel within
the health service.
Trial status
Participant recruitment, screening and enrollment are
ongoing.
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